Perspective Therapeutics reported encouraging interim results from its Phase 1/2a trial of \[212Pb\]VMT-α-NET in patients with advanced neuroendocrine tumors.
Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials.
Perspective Therapeutics is moving forward with dose escalation of [212Pb]VMT-α-NET, a targeted alpha-particle therapy, following positive safety data in a Phase 1/2a trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.